- Trial phase
- Approved
- Time to market
- Already approved and marketed since 2015. No new regulatory filing or label expansion is imminent based on available information.
- Why 3/10
- Empliciti is an already-approved, marketed drug with no pending regulatory decision or pivotal readout scheduled in the next ~12 months. It contributes roughly $80-100 million in annual sales, a negligible fraction of BMY's ~$48B+ total revenue, and BMY is a diversified large-cap pharma. No binary catalyst exists to drive a material share-price move from this single product.
Empliciti has no near-term binary catalysts. The next meaningful event to watch is the 2029-2030 patent expiry window, which could open the door to biosimilar competition, but that is several years away. For BMY investors, Empliciti is a non-factor; attention should be on the company's growth portfolio (Reblozyl, Breyanzi, Camzyos, Cobenfy) and the upcoming Eliquis patent cliff.
Price Chart
Executive Summary
Empliciti (elotuzumab) is an FDA-approved monoclonal antibody for relapsed/refractory multiple myeloma, developed by Bristol Myers Squibb (BMY) in partnership with AbbVie. First approved in 2015 and expanded in 2018, it is a commercial-stage drug with roughly $80-100 million in annual sales -- a very small contributor to BMY's overall revenue. The drug faces intense competition from daratumumab (Darzalex, ~$6B+ market), CAR-T therapies, and bispecific antibodies. Key US composition-of-matter patent protection runs to 2029 (potentially 2030 with pediatric exclusivity). No upcoming regulatory catalysts or pivotal readouts are identified, making Empliciti a mature, low-impact product within BMY's broad portfolio.
How It Works
Empliciti is a monoclonal antibody (a lab-made immune protein) that targets a protein called SLAMF7 found on multiple myeloma cancer cells and on natural killer cells of the immune system. By binding to both, it helps the immune system recognize and destroy cancer cells. It is always used in combination with other drugs, never alone.
Trial Status
Empliciti was approved by the FDA in November 2015 based on the Phase 3 ELOQUENT-2 trial, which showed a 30% reduction in the risk of disease progression when combined with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who had received 1-3 prior therapies. A second approval in 2018 expanded use in combination with pomalidomide and dexamethasone (EPd) for patients who had received at least two prior therapies. A Phase 3 trial (ELOQUENT-1) testing Empliciti in newly diagnosed, untreated multiple myeloma failed to show a survival benefit. Two additional BMY-sponsored trials (NCT03651128, NCT02719613) involving elotuzumab have completed as of early 2026.
The Two-Sided Case
Upcoming Catalysts
- No upcoming PDUFA dates, FDA Advisory Committee meetings, or pivotal Phase 3 readouts identified for Empliciti within the next 12 months.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BRISTOL MYERS SQUIBB CO 8-K BMY ·Originating report